Literature DB >> 2744079

[3H]Ro 19-6327: a reversible ligand and affinity labelling probe for monoamine oxidase-B.

A M Cesura1, M D Galva, R Imhof, E Kyburz, G B Picotti, M Da Prada.   

Abstract

This study demonstrated the existence of specific binding sites for [3H]Ro 19-6327 in human platelet membranes. This compound is a novel, time-dependent inhibitor of monoamine oxidase type B (MAO-B) and is structurally closely related to [3H]Ro 16-6491. The density of the sites labelled with high affinity by [3H]Ro 19-6327 was similar to that observed in previous studies with [3H]Ro 16-6491 as ligand. Binding was reversible at 20 degrees C and showed a relatively slow dissociation (t1/2 = 220 min). The dissociation rate was markedly decreased (t1/2 = greater than 24h) at 0 degrees C. MAO-B, but not MAO-A inhibitors, effectively prevented the binding of [3H]Ro 19-6327. Like [3H]Ro 16-6491, [3H]Ro 19-6327 is recognized as a substrate by MAO-B, being eventually deaminated by the enzyme. Since the deaminated aldehyde derivative of Ro 19-6327 did not inhibit MAO-B, a still unidentified reversible adduct, formed at the MAO-B active site, might explain the high potency and selectivity of [3H]Ro 19-6327. Incubation of the radioligand-enzyme complex from platelet and brain membranes with NaBH3CN and acetic acid (to pH 4.5) caused the irreversible incorporation of the radioactivity into a single polypeptide as shown by SDS-PAGE analysis. This polypeptide had a molecular weight identical to that of the MAO-B subunit, i.e. 58,000. The presence of unlabelled MAO-B inhibitors in the incubation mixture prevented the covalent incorporation of [3H]Ro 19-6327. The irreversible MAO-B inhibitor, [3H] pargyline, labelled a protein with a molecular weight identical to the protein labelled by [3H]Ro 19-6327.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2744079     DOI: 10.1016/0014-2999(89)90336-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex.

Authors:  M D Galva; G P Bondiolotti; M Olasmaa; G B Picotti
Journal:  J Neural Transm Gen Sect       Date:  1995

2.  Conventional Receptor Radioligand Binding Techniques Applied to the Study of Monoamine Oxidase.

Authors:  Andrew Holt
Journal:  Methods Mol Biol       Date:  2023

Review 3.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

4.  Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide.

Authors:  A M Cesura; R Kettler; R Imhof; M Da Prada
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.

Authors:  C J Bench; G W Price; A A Lammertsma; J C Cremer; S K Luthra; D Turton; R J Dolan; R Kettler; J Dingemanse; M Da Prada
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.

Authors:  N H Holford; T W Guentert; J Dingemanse; R Kettler
Journal:  Br J Clin Pharmacol       Date:  1994-06       Impact factor: 4.335

7.  Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain.

Authors:  Flora Ferrari; Simonetta Fiorentino; Laura Mennuni; Paolo Garofalo; Ornella Letari; Stefano Mandelli; Antonio Giordani; Marco Lanza; Gianfranco Caselli
Journal:  J Pain Res       Date:  2011-04-18       Impact factor: 3.133

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.